PMID- 32570992
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Jun 18
TI  - HLA Class I Allele Expression and Clinical Outcome in De Novo Metastatic Prostate 
      Cancer.
LID - 10.3390/cancers12061623 [doi]
LID - 1623
AB  - The prognostic value of human leukocyte antigen (HLA) class I molecules in 
      prostate cancer (PCa) remains unclear. Herein, we investigated the prognostic 
      relevance of the most frequently expressed HLA-A alleles in Greece (A*02:01 and 
      HLA-A*24:02) in de novo metastatic hormone-sensitive PCa (mPCa), which is a rare 
      and aggressive disease characterized by a rapid progression to 
      castration-resistance (CR) and poor overall survival (OS), contributing to almost 
      50% of PCa-related deaths. We identified 56 patients who had either progressed to 
      CR (these patients were retrospectively analyzed for the time to the progression 
      of CR and prospectively for OS) or had at least three months' follow-up 
      postdiagnosis without CR progression and, thus, were prospectively analyzed for 
      both CR and OS. Patients expressing HLA-A*02:01 showed poor clinical outcomes vs. 
      HLA-A*02:01(-)negative patients. HLA-A*24:02(-)positive patients progressed 
      slower to CR and had increased OS. Homozygous HLA-A*02:01 patients progressed 
      severely to CR, with very short OS. Multivariate analyses ascribed to both HLA 
      alleles significant prognostic values for the time to progression (TTP) to CR and 
      OS. The presence of HLA-A*02:01 and HLA-A*24:02 alleles in de novo mPCa patients 
      are significantly and independently associated with unfavorable or favorable 
      clinical outcomes, respectively, suggesting their possible prognostic relevance 
      for treatment decision-making in the context of precision medicine.
FAU - Stokidis, Savvas
AU  - Stokidis S
AD  - Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 
      Alexandras avenue, 11522 Athens, Greece.
FAU - Fortis, Sotirios P
AU  - Fortis SP
AD  - Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 
      Alexandras avenue, 11522 Athens, Greece.
FAU - Kogionou, Paraskevi
AU  - Kogionou P
AD  - Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 
      Alexandras avenue, 11522 Athens, Greece.
FAU - Anagnostou, Theodoros
AU  - Anagnostou T
AD  - Department of Urology, Saint Savas Cancer Hospital, 171 Alexandras avenue, 11522 
      Athens, Greece.
FAU - Perez, Sonia A
AU  - Perez SA
AD  - Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 
      Alexandras avenue, 11522 Athens, Greece.
FAU - Baxevanis, Constantin N
AU  - Baxevanis CN
AD  - Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 
      Alexandras avenue, 11522 Athens, Greece.
LA  - eng
GR  - project code: T1EDK-01404/European Regional Development Fund of the European 
      Union and Greek national funds through the Operational Program Competitiveness, 
      Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE./
PT  - Journal Article
DEP - 20200618
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7352811
OTO - NOTNLM
OT  - HLA-A*02:01
OT  - HLA-A*24:02
OT  - HLA-alleles
OT  - de novo metastatic prostate cancer
OT  - prognosis
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript; or in the decision to publish the results.
EDAT- 2020/06/24 06:00
MHDA- 2020/06/24 06:01
PMCR- 2020/06/18
CRDT- 2020/06/24 06:00
PHST- 2020/05/21 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/06/24 06:01 [medline]
PHST- 2020/06/18 00:00 [pmc-release]
AID - cancers12061623 [pii]
AID - cancers-12-01623 [pii]
AID - 10.3390/cancers12061623 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Jun 18;12(6):1623. doi: 10.3390/cancers12061623.